From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs

被引:179
作者
Morris, Hamilton [1 ]
Wallach, Jason [2 ]
机构
[1] New Sch Social Res, Dept Anthropol, New York, NY 10011 USA
[2] Univ Sci, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA
关键词
arylcyclohexylamines; research chemicals; methoxetamine; PCP; phencyclidine; ketamine; dissociatives; NMDA; folk pharmacology; Internet drug forums; RAPID-ACTING ANTIDEPRESSANT; PHENCYCLIDINE BINDING-SITES; ABUSE LIABILITY ASSESSMENT; NMDA RECEPTOR ANTAGONISTS; D-ASPARTATE ANTAGONIST; DISCRIMINATIVE STIMULUS; RECREATIONAL USE; STREET DRUG; KETAMINE; METHOXETAMINE;
D O I
10.1002/dta.1620
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
PCP or phencyclidine was discovered in 1956 and soon became a popular street drug. Dissociatives including PCP, ketamine, and dextromethorphan have been used non-medically for their mind-altering effects for over 60 years. Many of these compounds have also been used clinically and in legitimate research. At least 14 derivatives of PCP were sold for non-medical and illict use from the late 1960s until the 1990s. With the advent of the Internet, the drug market underwent a dramatic evolution. While initially gray-market chemical vendors offering dextromethorphan and ketamine thrived, most recently the market has shifted to legal high and online-based research chemical vendors. Starting with the first dissociative research chemical, 4-MeO-PCP in 2008, the dissociative research chemical market has rapidly evolved and currently comprises at least 12 dissociatives, almost half of which were unknown in the scientific literature prior to their introduction. Several of these, including methoxetamine, have reached widespread use internationally. A historical account of non-medical use of over 30 dissociative compounds was compiled from a diverse collection of sources. The first complete portrait of this underground market is presented along with the relevant legal, technological, and scientific developments which have driven its evolution. Copyright (C) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:614 / 632
页数:19
相关论文
共 190 条
[1]  
abuse Ketamine, 1979, FDA DRUG B
[2]  
ACMD, 2014, KET REP
[3]   SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THE N-METHYL-D-ASPARTATE ANTAGONIST DEXTRORPHAN IN PATIENTS WITH ACUTE STROKE [J].
ALBERS, GW ;
ATKINSON, RP ;
KELLEY, RE ;
ROSENBAUM, DM .
STROKE, 1995, 26 (02) :254-258
[4]   Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke [J].
Albers, GW ;
Clark, WM ;
Atkinson, RP ;
Madden, K ;
Data, JL ;
Whitehouse, MJ .
STROKE, 1999, 30 (03) :508-513
[5]   PCP - A REVIEW OF SYNTHETIC METHODS FOR FORENSIC CLANDESTINE INVESTIGATION [J].
ALLEN, AC ;
ROBLES, J ;
DOVENSKI, W ;
CALDERON, S .
FORENSIC SCIENCE INTERNATIONAL, 1993, 61 (2-3) :85-100
[6]   THE DISSOCIATIVE ANESTHETICS, KETAMINE AND PHENCYCLIDINE, SELECTIVELY REDUCE EXCITATION OF CENTRAL MAMMALIAN NEURONS BY N-METHYL-ASPARTATE [J].
ANIS, NA ;
BERRY, SC ;
BURTON, NR ;
LODGE, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (02) :565-575
[7]  
[Anonymous], 2014, The Hive. Xicori. PCM synthesis, Patent No. 2524855
[8]  
[Anonymous], 2014, The Hive. Xicori. Bioassay, Patent No. 1124496
[9]  
[Anonymous], 2009, NAT DRUG THREAT ASS
[10]  
[Anonymous], METH REP